One of the main experimental vaccines against him covid-19 in the world produced a immune response both in young adults like in old people, which improves the expectations of finding a formula for finish with the health crisis and stop the economic destruction caused by pandemic.
The vaccine, developed by the Oxford University, also generates minors Adverse effects between the old peoplesaid this Monday the pharmacist partner AstraZeneca Plc, which helps to manufacture the dose.
An effective vaccine could change the landscape in the battle against the coronavirus, which has killed more than 1.15 million people in the world, has paralyzed vast areas of the world economy and has transmuted the lifestyles of thousands of millions of people.
It is encouraging to see that immunogenicity responses were similar between older and younger adults and that reactogenicity – the property of a vaccine to be capable of producing common adverse reactions – was lower in older adults, where the severity of the disease covid-19 is higher, “said an AstraZeneca spokesperson.
The results bring together a body of evidence demonstrating the safety and immunogenicity of AZD1222, “he added.
The AstraZeneca and Oxford University vaccine is expected to be one of the first to gain regulatory approval in the Western Hemisphere, along with candidates from other industry giants such as Pfizer and BioNTech.
The news that older people will develop immune responses to the virus is positive because people’s defense capacity weakens with aging, exposing a significant segment of populations to disease.
If effective, the vaccine could allow the world to return to certain levels of normality after a tumultuous year due to the pandemic.
Video: Lungs, liver and brain, organs most affected after suffering from covid-19 (Dailymotion)
British Health Secretary Matt Hancock said the vaccine was not yet ready but his portfolio was preparing the logistics for the possible rollout of the immunization in the first half of 2021.
Asked whether people would receive the vaccine this year, he replied to the BBC:
I do not rule it out but it is not the main expectation. “
The program is progressing well, (but) we are not there yet, “Hancock said.
VECTOR VIRAL DE GRIPE
Work by experts at Oxford University on the vaccine began in January. Called AZD1222 or ChAdOx1 nCoV-19, the viral vector in the formula is made from a weaker version of a flu virus that causes infections in chimpanzees.
The chimpanzee flu virus was tapped in laboratories to include the genetic sequence of the protein that the coronavirus uses to enter human cells. The human body is then expected to be able to attack the new coronavirus if it detects it again.
The immunogenicity blood tests carried out in elderly people are similar to the results of trials released in July that showed that the vaccine generated “robust immune responses” in a group of healthy adults between 18 and 55 years old, reported the diary Financial Times early Monday.
Details of these studies are expected to be released shortly in a medical journal, the newspaper said, without offering details on the name of the publication.